between the exposure to smoking (packyears) and severity of ED was assessed before the follow-up. The ED status between patients who stopped smoking after NRT and those who continued during the follow-up was then compared before and after the follow-up. RESULTSThe severity of ED correlated significantly with the level of exposure to smoking. Age and ED status before the follow-up were not significantly different between 118 patients who stopped (ex-smokers) and 163 who continued smoking (current smokers). After 1 year the ED status improved in ≥ 25% of exsmokers but in none of the current smokers; 2.5% of ex-smokers and 6.8% of current smokers had a deterioration in ED. Ex-smokers had a significantly better ED status after the follow-up ( P = 0.009). Among ex-smokers, patients with advanced ED and those who were older had less improvement. CONCLUSIONThere is a strong association between the intensity of cigarette smoking and degree of ED. Stopping cigarette smoking can improve ED in a considerable proportion of smokers. Age and the severity of ED before stopping are inversely related to the chance of improvement.
Background: Sepsis is a syndrome involving physiological, pathological, and biochemical abnormalities caused by infection and leads to the dysfunction of various organs, including the liver and kidneys. It can lead to high mortality rates. Objectives: This study aimed to evaluate the hepatic, renal, and coagulation diagnostic markers in patients with sepsis. Methods: This cross-sectional analytical study was performed on patients with sepsis admitted to Abadan and Khorramshahr educational hospitals during March 21 2019-March 19, 2020. The hospital information system (HIS) collected the information of 305 patients with sepsis, including hepatic, coagulation, and renal diagnostic factors, as well as age and gender. Results: It was observed that the mean of blood sugar (BS) (145.82 ± 105.10 mg/dL), BUN (29.64 ± 27.41 mg/dL), and creatinine (1.69±1.9 mg/dL) in sepsis patients was higher than normal. In addition, the mean of diagnostic markers of the liver, including ALT (47.27 ± 76.63 U/L), AST (74.38 ± 163.96 U/L), LDH (684.69 ± 383.96 U/L), total bilirubin (1.39 ± 1.02 mg/dL), and direct bilirubin (0.60 ± 0.65 mg/dL), was higher than normal. The mean of PT (16.73±9.31 sec) and INR (1.72 ± 1.53) was also higher than the normal level. Conclusions: In hospitalized patients with sepsis, BS, renal diagnostic markers, hepatic diagnostic markers, and coagulation markers are higher than normal, indicating the destructive effect of sepsis on kidney and liver function.
An association between migraine and ischaemic stroke has been observed for many years, but the exact mechanisms by which migraine can lead to stroke are still unknown. The purpose of this study was to determine the prevalence of migraine headaches in patients with ischaemic stroke. In this prospective cohort study, we assessed 323 patients with ischaemic stroke; these diagnoses were assigned based on the International Headache Society criteria for migraine with or without aura. Patients were recruited without major risk factors such as stroke, hypertension, hyperlipidaemia, diabetes, taking oral contraceptive pills, history of drug abuse and trauma in issue of their Stroke. Data were collected via a written questionnaire upon admission and were analysed with SPSS version 16 software. Comparisons were performed using Mann-Whitney's U test and chi-square and t-test. Migraine headache was present in 11.2% (36 of 323) of patients, 8.1% of women and 3.1% of men. Migraine prevalence was highest in the age over 60 years. There was a history of migraine without aura for over 2 years in 6.2% of patients with ischaemic stroke. Also, we found no significant correlation between migraine headache and location of the lesion in patients with ischaemic stroke.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.